Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial Meeting Abstract
| Authors: | Morris, M. J.; Fong, L.; Petrylak, D. P.; Sartor, A. O.; Higano, C. S.; Pagliaro, L. C.; Alva, A. S.; Appleman, L. J.; Tan, W.; Vaishampayan, U. N.; Porcu, R.; Tayama, D.; Kadel, E. E.; Yuen, K. C. Y.; Datye, A.; Armstrong, A. J. |
| Abstract Title: | Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual Conference |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368302408 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.5565 |
| Notes: | Meeting Abstract: 5565 -- Source: Wos |
